Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/1/e006833corr1.full

Similar Items

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1
by: Filippo de Braud, et al.
Published: (2023-06-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
by: Stephen V. Liu, MD, et al.
Published: (2023-02-01)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
by: Vamsidhar Velcheti, et al.
Published: (2022-02-01)

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
by: Arjun Bhadhuri, et al.
Published: (2019-12-01)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
by: Rebekah Rittberg, et al.
Published: (2023-05-01)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01)

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
by: Choong-kun Lee, et al.
Published: (2022-10-01)

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
by: Balazs Halmos, et al.
Published: (2020-12-01)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
by: Lauren Jones, et al.
Published: (2022-11-01)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
by: Yoichi Nishii, et al.
Published: (2022-07-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
by: Romain-David Seban, et al.
Published: (2020-08-01)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
by: Christopher A. Lemmon, MD, et al.
Published: (2022-07-01)

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
by: Paul Zarogoulidis, et al.
Published: (2017-01-01)

NTC'S dictionary of proverbs and cliches /
by: Bertram, Anne, et al.
Published: (1993)

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
by: Antonio Passaro, et al.
Published: (2021-06-01)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
by: Chijioke Nze, et al.
Published: (2023-07-01)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
by: Toshiharu Hirose, et al.
Published: (2023-01-01)

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
by: Edoardo Lenci, et al.
Published: (2021-03-01)

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
by: Yasushi Goto, MD, PhD, et al.
Published: (2022-09-01)

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
by: Dolores Isla, et al.
Published: (2023-01-01)

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
by: Ying Liu, et al.
Published: (2024-02-01)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
by: Lan-Lan Pang, et al.
Published: (2023-01-01)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
by: Camilo Jimenez, et al.
Published: (2020-08-01)

NTC's dictionary of American slang and colloquial expressions /
by: 379550 Spears, Richard A.
Published: (2000)

NTC's new college French and English dictionary
Published: (1997)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
by: Jeng-Shiuan Tsai, et al.
Published: (2022-11-01)

Integration of the standards CWA 15793:2008, NTC-ISO 9001:2008, NTC-ISO 17025:2005 and NTC OHSAS 18001:2007 in the National Veterinary Diagnostic Laboratory of the Colombian Agricultural and Livestock Institute (ICA
by: Alba Bernarda Porras Santiago
Published: (2018-01-01)

First-Line Treatment of _ALK_-Positive NSCLC
by: Hasna Bouchaab
Published: (2020-11-01)

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice
by: Magdalena Knetki-Wróblewska, et al.
Published: (2024-01-01)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
by: Fu Wenfan, et al.
Published: (2023-10-01)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
by: Zoran Andric, MD, et al.
Published: (2023-02-01)

Methodological proposal for the integration of a document management system based on NTC ISO 9001, NTC GP1000 and ISO / IEC 17025
by: Yanneth Garcia Melo, et al.
Published: (2016-07-01)

First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study
by: Dominik Soll, et al.
Published: (2024-02-01)

Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report
by: Paola Maria Medusa, et al.
Published: (2022-11-01)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
by: Simiao Wang, et al.
Published: (2023-06-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
by: Zhuo‐Miao Ye, et al.
Published: (2023-03-01)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
by: Marie-Hélène Denault, et al.
Published: (2021-11-01)